Replication study to confirm the role of CYP2D6 polymorphism rs1080985 on donepezil efficacy in alzheimer's disease patients

Diego Albani, Filippo Martinelli Boneschi, Gloria Biella, Giacomo Giacalone, Sara Lupoli, Francesca Clerici, Luisa Benussi, Roberta Ghidoni, Daniela Galimberti, Rosanna Squitti, Stefania Mariani, Annamaria Confaloni, Giuseppe Bruno, Claudio Mariani, Elio Scarpini, Giuliano Binetti, Giuseppe Magnani, Massimo Franceschi, Gianluigi Forloni

Research output: Contribution to journalArticle


Alzheimer's disease (AD) is a neurodegenerative disorder often treated with donepezil, an acetylcholinesterase inhibitor. Response to donepezil is variable, probably based on patients' genetic background in donepezil metabolizing enzymes, including cytochrome 2D6 (CYP2D6). We evaluated the association between clinical response to donepezil and a common variant (rs1080985) of CYP2D6, previously reported to be associated with poor response to the drug. In a sample of 415 AD cases, we found evidence of association between rs1080985 and response to donepezil after 6 months of therapy (OR [95% CI]: 1.74 [1.01-3.00], p = 0.04). Rs1080985 might be useful as predictor of poor response to short-term donepezil treatment.

Original languageEnglish
Pages (from-to)745-749
Number of pages5
JournalJournal of Alzheimer's Disease
Issue number4
Publication statusPublished - 2012



  • Alzheimer's disease
  • apolipoprotein E
  • CYP2D6
  • donepezil
  • pharmacogenetics
  • rs1080985

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Geriatrics and Gerontology
  • Clinical Psychology

Cite this